(NASDAQ: VCEL) Vericel's forecast annual revenue growth rate of 18.4% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.39%, and while it is forecast to beat the US market's average forecast revenue growth rate of 14.36%.
Vericel's revenue in 2026 is $276,259,000.On average, 10 Wall Street analysts forecast VCEL's revenue for 2026 to be $16,743,773,139, with the lowest VCEL revenue forecast at $15,973,185,957, and the highest VCEL revenue forecast at $17,676,802,942. On average, 10 Wall Street analysts forecast VCEL's revenue for 2027 to be $19,797,694,410, with the lowest VCEL revenue forecast at $18,560,084,693, and the highest VCEL revenue forecast at $21,535,830,453.
In 2028, VCEL is forecast to generate $23,400,367,159 in revenue, with the lowest revenue forecast at $21,393,693,159 and the highest revenue forecast at $25,843,098,070.